{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:33:36Z","timestamp":1764401616750},"reference-count":18,"publisher":"American Society for Microbiology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The immunogenicity and safety of an inactivated cell culture Japanese encephalitis vaccine (CC-JEV) were compared with those of an inactivated mouse brain-derived Japanese encephalitis vaccine (MB-JEV) in phase III clinical multicenter trials conducted in children. The vaccines contain the same Japanese encephalitis virus strain, the Beijing-1 strain. Two independent clinical trials (trials 1 and 2) were conducted. Trial 1 was conducted in 468 healthy children. Each subject was injected with 17 \u03bcg per dose of either CC-JEV or MB-JEV, and the immunogenicity and safety of the vaccines were investigated. Trial 1 showed that CC-JEV was more immunogenic and reactive than MB-JEV at the same dose. Therefore, to adjust the immunogenicity of CC-JEV to that of MB-JEV, a vaccine that has had a good track record regarding its efficacy for a long time, trial 2 was conducted in 484 healthy children. To improve the stability, CC-JEV was converted from a liquid type to a freeze-dried type of vaccine. Each subject was injected subcutaneously with either 4 \u03bcg per dose of CC-JEV, 8 \u03bcg per dose of CC-JEV, or 17 \u03bcg per dose of MB-JEV twice, at an interval of 2 to 4 weeks, followed by an additional booster immunization 1 to 15 months after the primary immunization. Based on the results of trial 2, 4 \u03bcg per dose of the freeze-dried CC-JEV (under the label Encevac) was selected as a substitute for the MB-JEV. Encevac was approved and launched in 2011 and has since been in use as a 2nd-generation Japanese encephalitis vaccine in Japan. (These studies have been registered at the JapicCTI under registration no. JapicCTI-132063 and JapicCTI-080586 for trials 1 and 2, respectively.)<\/jats:p>","DOI":"10.1128\/cvi.00377-13","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T07:02:17Z","timestamp":1386831737000},"page":"188-195","source":"Crossref","is-referenced-by-count":25,"title":["Phase III Clinical Trials Comparing the Immunogenicity and Safety of the Vero Cell-Derived Japanese Encephalitis Vaccine Encevac with Those of Mouse Brain-Derived Vaccine by Using the Beijing-1 Strain"],"prefix":"10.1128","volume":"21","author":[{"given":"Chiaki","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuo","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaneshige","family":"Iribe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2013,12,11]]},"reference":[{"key":"key20180919073721_B1","first-page":"312","article-title":"Japanese encephalitis vaccines","volume-title":"Vaccines","author":"Halstead","year":"2012","edition":"6th ed."},{"key":"key20180919073721_B2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0042-6822(87)90144-9","article-title":"Complete nucleotide sequence of the Japanese encephalitis virus genome RNA","volume":"161","author":"Sumiyoshi","year":"1987","journal-title":"Virology"},{"key":"key20180919073721_B3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1708-8305.2007.00134.x","article-title":"Japanese encephalitis for a reference to international travelers","volume":"14","author":"Oya","year":"2007","journal-title":"J. Travel Med."},{"key":"key20180919073721_B4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(01)05967-0","article-title":"Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study","volume":"358","author":"Bista","year":"2001","journal-title":"Lancet"},{"key":"key20180919073721_B5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"key20180919073721_B6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/biol.2002.0345","article-title":"Development of Vero cell-derived inactivated Japanese encephalitis vaccine","volume":"30","author":"Sugawara","year":"2002","journal-title":"Biologicals"},{"key":"key20180919073721_B7","first-page":"227","article-title":"Acute disseminated encephalomyelitis and pediatric multiple sclerosis: current states in Japan","volume":"42","author":"Yamaguchi","year":"2010","journal-title":"No To Hattatsu"},{"key":"key20180919073721_B8","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.vaccine.2012.01.054","article-title":"Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated)","volume":"30","author":"Kikukawa","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073721_B9","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1016\/j.vaccine.2012.07.034","article-title":"Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JeBIK-V) in children","volume":"30","author":"Okada","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073721_B10","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"key20180919073721_B11","doi-asserted-by":"publisher","first-page":"8669","DOI":"10.1016\/j.vaccine.2011.08.117","article-title":"Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine Ixiaro","volume":"29","author":"Schuller","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073721_B12","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0264-410X(02)00772-7","article-title":"Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells","volume":"21","author":"Abe","year":"2003","journal-title":"Vaccine"},{"key":"key20180919073721_B13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1442-200X.1988.tb02516.x","article-title":"Japanese encephalitis vaccine","volume":"30","author":"Oya","year":"1988","journal-title":"Acta Paediatr. Jpn."},{"key":"key20180919073721_B14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2307\/2529457","article-title":"Significance testing to establish equivalence between treatments, with special reference to data in the form of 2\u00d72 tables","volume":"33","author":"Dunnett","year":"1977","journal-title":"Biometrics"},{"key":"key20180919073721_B15","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat. Med."},{"key":"key20180919073721_B16","doi-asserted-by":"publisher","first-page":"i22","DOI":"10.1136\/jnnp.2003.034256","article-title":"Inflammatory\/post-infectious encephalomyelitis","volume":"75","author":"Bennetto","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"key20180919073721_B17","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archneur.62.11.1673","article-title":"Acute disseminated encephalomyelitis: an update","volume":"62","author":"Menge","year":"2005","journal-title":"Arch. Neurol."},{"key":"key20180919073721_B18","volume-title":"The immunological basis for immunization series: module 13: Japanese encephalitis","author":"WHO","year":"2010"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00377-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:50:24Z","timestamp":1627591824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00377-13"}},"subtitle":[],"editor":[{"given":"M. F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,11]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,29]]},"published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1128\/CVI.00377-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00377-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,11]]}}}